Discontinued — last reported Q1 '26
Boston Scientific Global Crm Reporting Unit — Net Sales remained flat by 0.0% to $578.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $578.00M to $578.00M. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates growing market adoption or successful product launches in the cardiac rhythm management space, while a decrease may signal increased competition or market saturation.
This metric represents the total revenue generated from the sale of cardiac rhythm management devices, including pacemak...
Comparable to cardiac rhythm management revenue segments reported by major medical device competitors like Medtronic or Abbott Laboratories.
bsx_segment_global_crm_reporting_unit_net_sales| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $524.00M | $512.00M | $514.00M | $519.00M | $541.00M | $519.00M | $548.00M | $566.00M | $552.00M | $575.00M | $576.00M | $561.00M | $578.00M | $590.00M | $578.00M | $578.00M |
| QoQ Change | — | -2.3% | +0.4% | +1.0% | +4.2% | -4.1% | +5.6% | +3.3% | -2.5% | +4.2% | +0.2% | -2.6% | +3.0% | +2.1% | -2.0% | +0.0% |
| YoY Change | — | — | — | — | +3.2% | +1.4% | +5.6% | +4.6% | +6.4% | +4.9% | +1.8% | +1.6% | +0.5% | +2.4% | +3.0% | +0.0% |